CASI Pharmaceuticals, Inc. (CASI)

NASDAQ: CASI · IEX Real-Time Price · USD
2.60
-0.29 (-10.03%)
At close: Sep 30, 2022 4:00 PM
2.56
-0.04 (-1.54%)
After-hours: Sep 30, 2022 4:28 PM EDT
-10.03%
Market Cap 35.38M
Revenue (ttm) 34.91M
Net Income (ttm) -32.10M
Shares Out 13.61M
EPS (ttm) -2.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date Jun 2, 2022
Volume 23,322
Open 2.66
Previous Close 2.89
Day's Range 2.60 - 2.79
52-Week Range 2.24 - 12.40
Beta 0.44
Analysts Buy
Price Target 23.12 (+789.2%)
Earnings Date Nov 10, 2022

About CASI

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and... [Read more...]

Industry Biotechnology
IPO Date Jun 11, 1996
CEO Wei-Wu He
Employees 176
Stock Exchange NASDAQ
Ticker Symbol CASI
Full Company Profile

Financial Performance

In 2021, CASI's revenue was $30.17 million, an increase of 99.25% compared to the previous year's $15.14 million. Losses were -$36.65 million, -24.09% less than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for CASI stock is "Buy." The 12-month stock price forecast is 23.12, which is an increase of 789.23% from the latest price.

Price Target
$23.12
(789.23% upside)
Analyst Consensus: Buy
Stock Forecasts

News

CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET

ROCKVILLE, Md. and BEIJING , Sept.

1 week ago - PRNewsWire

ALJ Regional Hldgs (NASDAQ:ALJJ), CASI Pharmaceuticals (NASDAQ:CASI) – $2.2 Million Bet On Terns Pharmaceuticals? Che...

The Dow Jones closed higher by around 193 points on Thursday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: ALJJLDITERN
3 weeks ago - Benzinga

CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying

The Dow Jones tumbled by over 1,000 points on Friday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: HCWBHSDT
1 month ago - Benzinga

CASI Pharmaceuticals, Inc. (CASI) Reports Q2 Loss, Tops Revenue Estimates

CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 13.85% and 19.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS

ROCKVILLE, Md. and BEIJING , Aug. 12, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics a...

1 month ago - PRNewsWire

CASI PHARMACEUTICALS TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL AUGUST 12, 2022

ROCKVILLE, Md. and BEIJING , Aug. 5, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics an...

1 month ago - PRNewsWire

CASI PHARMACEUTICALS ANNOUNCES ITS PARTNER, PRECISION AUTOIMMUNE THERAPEUTICS CO., LTD HAS COMPLETED FIRST-ROUND FINA...

~ Precision Autoimmune Therapeutics (PAT) Announced the completion of first-round financing of the equivalent of approximately US $21 million ~ ~ CASI holds 15% equity stake in PAT ~ ~ PAT will pay CASI...

2 months ago - PRNewsWire

Why Is CASI Pharmaceuticals (CASI) Stock Up 700% Today?

CASI Pharmaceuticals (CASI) stock rocketed higher in pre-market trading this morning but it's not due to any positive news from the company. The post Why Is CASI Pharmaceuticals (CASI) Stock Up 700% Today?

4 months ago - InvestorPlace

CASI Pharmaceuticals stock falls after reverse split takes effect

Shares of CASI Pharmaceuticals Inc. CASI, +18.01% are actually falling in premarket trading Thursday, as a 1-for-10 reverse stock split took effect. While some quote services may still be showing a big ...

4 months ago - Market Watch

CASI PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT

ROCKVILLE, Md. and BEIJING , May 26, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics an...

4 months ago - PRNewsWire

CASI PHARMACEUTICALS ENTERES INTO SUBLICENSE AGREEMENT WITH TIANSHI PHARMACEUTICALS FOR ANTI-CD38 MONOCLONAL ANTIBODY...

~ CASI to receive upfront payment of $10 million in two instalments ~ ~ CASI through its wholly-owned PRC subsidiary, will hold 15% equity of TIANSHI ~ ROCKVILLE, Md. and BEIJING, May 24, 2022 /PRNewswi...

4 months ago - PRNewsWire

CASI Pharmaceuticals, Inc. (CASI) Reports Q1 Loss, Misses Revenue Estimates

CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 40% and 0.96%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS

ROCKVILLE, Md. and BEIJING , May 12, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics an...

4 months ago - PRNewsWire

CASI PHARMACEUTICALS TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL MAY 12, 2022

ROCKVILLE, Md. and BEIJING, May 2, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and ...

5 months ago - PRNewsWire

Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework

According to a Bloomberg report, U.S. regulators could reportedly have full access to auditing reports from most of the 200-plus China-based companies listed in New York in mid-2022. In the drafting sta...

Other symbols: BGNEHCMZLAB
6 months ago - Benzinga

CASI PHARMACEUTICALS STATEMENT ON STATUS UNDER HOLDING FOREIGN COMPANIES ACCOUNTABLE ACT

ROCKVILLE, Md. and BEIJING , April 1, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics a...

6 months ago - PRNewsWire

CASI PHARMACEUTICALS ANNOUNCES FULL-YEAR 2021 FINANCIAL RESULTS AND FOURTH QUARTER 2021 EVOMELA® REVENUE

~ EVOMELA® (melphalan for injection) Fourth Quarter 2021 Revenue Continues Strong Upward Trend, exceeding guidance ~ ROCKVILLE, Md. and BEIJING, March 28, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc....

6 months ago - PRNewsWire

CASI PHARMACEUTICALS TO REPORT FOURTH QUARTER AND YEAR END 2021 FINANCIAL RESULTS AND HOST CONFERENCE CALL MARCH 28, ...

ROCKVILLE, Md. and BEIJING , March 23, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics ...

6 months ago - PRNewsWire

CASI PHARMACEUTICALS ANNOUNCES RENEWAL OF EXCLUSIVE DISTRIBUTION AGREEMENT FOR EVOMELA® IN CHINA

ROCKVILLE, Md. and BEIJING, March 4, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics an...

6 months ago - PRNewsWire

CASI PHARMACEUTICALS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL-YEAR 2021 REVENUES AND PROVIDES BUSINESS UPDATES

ROCKVILLE, Md. and BEIJING, Feb. 16, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics an...

7 months ago - PRNewsWire

CASI PHARMACEUTICALS PARTNER, BIOINVENT, ANNOUNCES BI -1206 GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA FOR THE T...

ROCKVILLE, Md and LUND, Sweden , Jan. 20, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeuti...

8 months ago - PRNewsWire

CASI PHARMACEUTICALS ANNOUNCES CNCT19 (CD19 CAR-T) GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA

ROCKVILLE, Md. and BEIJING, Jan. 18, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics an...

8 months ago - PRNewsWire

CASI PHARMACEUTICALS, RECEIVES NASDAQ DEFICIENCY NOTICE

ROCKVILLE, Md. and BEIJING, Jan. 3, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and...

8 months ago - PRNewsWire

CASI PHARMACEUTICALS ANNOUNCES STOCK REPURCHASE PROGRAM

ROCKVILLE, Md. and BEIJING , Dec. 17, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), (the "Company" or "CASI"), a U.S. biopharmaceutical company focused on developing and commercializin...

9 months ago - PRNewsWire